Polyketide compounds having anti-inflammatory activity and methods for producing and using same

By isolating and fermenting Alternaria sp. HJT-Y7 from Rhodiola tibetica and purifying novel polyketide epimers, new anti-inflammatory compounds are obtained, demonstrating potent inhibitory effects on NO release.

JP2024542324AActive Publication Date: 2024-11-14DALIAN UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024533327
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-13
Filing Date
2022-06-28
Publication Date
2024-11-14
Estimated Expiration
2042-06-28

AI Technical Summary

Technical Problem

Current technologies have not fully exploited the potential of plant endophytic bacterial resources for discovering new biologically active compounds, particularly polyketides with anti-inflammatory activity.

Method used

Isolation and fermentation of Alternaria sp. HJT-Y7 from Rhodiola tibetica, followed by a multi-step chromatography process to obtain novel polyketide epimers, specifically Compound 1 and Compound 2, which are then characterized by NMR and CD spectroscopy.

Benefits of technology

Compound 1 and Compound 2 exhibit significant anti-inflammatory activity, inhibiting NO release at concentrations as low as 5 μM, outperforming positive controls.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542324000001_ABST
    Figure 2024542324000001_ABST
Patent Text Reader

Abstract

The present invention discloses a polyketide compound with anti-inflammatory activity and its preparation and use, which belongs to the field of pharmaceutical technology. The present application isolates Alternaria sp. HJT-Y7 from the leaf part of Rhodiola tibetica, and the obtained Alternaria sp. HJT-Y7 is subjected to solid fermentation, and two polyketide compounds are obtained by a series of isolation and purification methods, both of which have good anti-inflammatory activity, providing a new approach for the development of anti-inflammatory drugs.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of pharmaceutical technology, in particular to a novel polyketide epimer having anti-inflammatory activity and its preparation and use. [Background technology]

[0002] Medicinal plant endophytic fungi are diverse, and each endophytic fungus has a wealth of secondary metabolites, and currently, a large number of biologically active substances such as alkaloids, polypeptides, polyketides, and terpenoids have been discovered from the secondary metabolites of endophytic fungi, and these secondary metabolites not only have the same or similar biological activities as those of the host plant, such as antibacterial, anti-inflammatory, antitumor, antihyperglycemic, and antiparasitic, but also have many new biological activities. Therefore, the secondary metabolites of medicinal plant endophytic fungi are a huge potential medicinal substance resource storehouse, with good prospects for development. Summary of the Invention [Problem to be solved by the invention]

[0003] The present invention has been made in view of the above, and aims to provide a polyketide compound with anti-inflammatory activity, and its preparation and use. The present invention is to fully utilize the plant endophytic fungus resources by conducting research on plant endophytic fungi, isolating Alternaria sp. HJT-Y7 from the leaf part of Rhodiola tibetica, which was deposited in the General Microorganism Center of China Committee for the Preservation and Management of Microorganisms on May 6, 2022, with the deposit number CGMCC No. 40166, and the depository address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, and the obtained Alternaria sp. HJT-Y7 is subjected to solid fermentation, and separated using a series of separation and purification methods to obtain a pair of polyketide epimers with a new structure, providing a new lead compound for the development of drugs. [Means for solving the problem]

[0004] The object of the present invention can be achieved by the following technical means.

[0005] According to one aspect of the present invention, there is provided a polyketide compound having the structure shown in the formula below, or a pharma- ceutically acceptable salt thereof. [ka]

[0006] According to another aspect of the present invention, there is provided an endophytic fungus of the genus Alternaria (Alternaria sp.) HJT-Y7, which was deposited at the Center of Ordinary Microorganisms of the China Commission on Microbial Species Preservation and Management on May 6, 2022, with the deposit number CGMCC No. 40166, and the address of the depository institution is No. 3, Hall, No. 1, Beichen West Road, Chaoyang District, Beijing.

[0007] According to another aspect of the present invention, there is provided a method for producing the polyketide compound, which mainly comprises the following steps (1) and (2): Step (1): The above-mentioned Alternaria sp. HJT-Y7 is inoculated into a fungal No. 4 medium and cultured under shaking. The resulting fermentation liquid is inoculated into a rice solid medium together with the mycelium, and left to stand at 20-30°C for 10-40 days for fermentation to obtain a solid fermentation product. Step (2): The solid fermentation product obtained in step (1) is extracted with methanol and filtered. The obtained extract is loaded onto a silica gel chromatography column, and gradient elution is performed using chloroform / methanol with a volume ratio of 100:0 to 0:100 as the mobile phase. Based on the TLC results, fractions 1 to 16 are obtained in sequence. Fraction 7 is loaded onto a silica gel chromatography column, and gradient elution is performed using petroleum ether / ethyl acetate with a volume ratio of 10:1 to 10:9 as the mobile phase. Based on the TLC results, fractions 7-1 to 7-10 are obtained in sequence. Fraction 7-6 is loaded onto a Sephadex LH-20 gel column, and elution is performed using a dichloromethane / methanol mixture with a volume ratio of 1:1 as the mobile phase. Fractions 7-6-1 to 7-6-6 are obtained in sequence. Fraction 7-6-3 is loaded onto an Agilent C18 high performance liquid chromatography column, and elution is performed using a 55% aqueous methanol solution as the mobile phase to obtain compound 1 and compound 2.

[0008] Furthermore, the conditions for the shaking culture in step (1) are 20 to 30° C. and 100 to 200 r / min.

[0009] Furthermore, the solid rice medium in step (1) is obtained by preparing rice and pure water in a mass / volume ratio of 80:80 to 120 g / ml.

[0010] Furthermore, the above-mentioned fungal No. 4 medium in step (1) is composed of 2% mannitol, 2% glucose, 0.5% yeast extract, 1% peptone, 0.05% KH2PO4, 0.03% MgSO4·7H2O, 0.1% corn steep liquor, and deionized water.

[0011] Furthermore, during the gradient elution in step (2), the volume ratios of chloroform to methanol are 100:0, 100:1, 100:2, 100:3, 100:5, 100:10, and 0:100.

[0012] Furthermore, the volume ratios of petroleum ether to ethyl acetate during the gradient elution in step (2) are 10:1, 10:3, 10:5, 10:6, 10:7, and 10:9.

[0013] The present invention further provides a pharmaceutical composition comprising the above polyketide compound or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.

[0014] The present invention further provides use of the above-mentioned polyketide compound, or a pharma- ceutically acceptable salt thereof, or the above-mentioned pharmaceutical composition for the manufacture of an anti-inflammatory drug. Effect of the Invention

[0015] Compared with the prior art, the present invention has the following advantages: In order to utilize endophytic fungal resources, the present invention conducted research on endophytic fungi to discover new polyketide active compounds. The results of anti-inflammatory activity experiments showed that, compared with the model group, compound 1 and compound 2 inhibited the release of NO to different degrees depending on the concentration, and at a concentration of 5 μM, they showed better inhibitory ability than the positive control group, indicating that compound 1 and compound 2 have good anti-inflammatory effects. [Brief description of the drawings]

[0016] In order to more clearly explain the embodiments of the present invention, the drawings relating to the embodiments will be briefly described below.

[0017] [Figure 1] FIG. 1 is a 1H-NMR diagram of compound 1 isolated in Example 1. [Diagram 2] FIG. 13C-NMR diagram of compound 1 isolated in Example 1. [Diagram 3] FIG. 1 is an HSQC diagram of compound 1 isolated in Example 1. [Figure 4] FIG. 1 is an HMBC diagram of compound 1 isolated in Example 1. [Diagram 5] FIG. 2 is a NOESY diagram of compound 1 separated in Example 1. [Figure 6] FIG. 1H-NMR diagram of compound 2 isolated in Example 1. [Figure 7] FIG. 13C-NMR diagram of compound 2 isolated in Example 1. [Figure 8] FIG. 1 is an HSQC diagram of compound 2 separated in Example 1. [Figure 9] FIG. 2 is an HMBC diagram of compound 2 separated in Example 1. [Figure 10] FIG. 2 is a NOESY diagram of compound 2 separated in Example 1. [Figure 11] FIG. 2 is a CD diagram of compound 1-2 isolated in Example 1. [Figure 12] FIG. 4 is a DP4+ diagram of compound 1-2 isolated in Example 1. [Figure 13] FIG. 2 is a graph showing the anti-inflammatory effect of compound 1-2 isolated in Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present invention will be described in detail below with reference to examples, but the embodiments of the present invention are not limited thereto. The examples described below are only a part of the examples of the present invention, and it is obvious that other similar examples obtained by those skilled in the art without creative labor are included in the scope of protection of the present invention. Unless otherwise stated, all experimental methods used in the present invention are conventional methods, and all experimental equipment, materials, reagents, etc. used are commercially available.

[0019] Example 1 The method for producing a polyketide compound mainly includes steps (1) and (2).

[0020] (1) Fermentation: Alternaria sp. HJT-Y7, an endophytic fungus of the genus Alternaria, collected from the leaves of Tibetan Rhodiola rosea, was shake-cultured in fungal medium No. 4 (prepared with 2% mannitol, 2% glucose, 0.5% yeast extract, 1% peptone, 0.05% KH2PO4, 0.03% MgSO4·7H2O, 0.1% corn steep liquor, and deionized water). The culture conditions were 28℃ and 180r / min. The fermented liquid obtained by shaking culture was inoculated into an Erlenmeyer flask containing rice solid medium (prepared with a mass and volume ratio of rice and pure water of 80g:110mL) together with mycelium, and the mixture was left to stand at 28℃ for 40 days for fermentation, to obtain a solid fermentation product.

[0021] (2) Extraction and separation of metabolites: The solid fermentation product obtained in step (1) is ultrasonically extracted with an equal volume of methanol, filtered through eight layers of gauze, the extract is separated from the mycelium and rice, the extract is concentrated, and the extract is loaded into a silica gel chromatography column for separation, where 300-400 mesh silica gel is used as the stationary phase, and chloroform / methanol is used as the mobile phase for gradient elution, the gradient is chloroform:methanol=100:0, 100:1, 100:2, 100:3, 100:5, 100:10, 0:100 (v / v) in order, the flow rate of the eluent (mobile phase) is 30 mL / min, and 10,000 mL is eluted for each gradient, and elution is performed. The eluate (one bottle for every 500 mL) was collected and concentrated. According to the TLC results, the bottles were combined to obtain fractions 1-16 in sequence. Fraction 7 was loaded onto a silica gel chromatography column for separation, where 200-300 mesh silica gel was used as the stationary phase, petroleum ether / ethyl acetate was used as the mobile phase for gradient elution, the gradient was petroleum ether:ethyl acetate=10:1, 10:3, 10:5, 10:6, 10:7, 10:9 (v / v) in sequence, and the flow rate of the eluent was 30 mL / min. The eluate (one bottle for every 500 mL) was collected and concentrated. According to the TLC results, the bottles were combined to obtain fractions 7-1-7-10 in sequence. Fraction 7-6 was loaded onto a Sephadex column for separation. The mixture was loaded onto an LH-20 gel column for separation, where the mobile phase was a mixture of dichloromethane / methanol = 1:1 (v / v), the flow rate was 0.3mL / min, the eluate (collected once every 10ml) was collected, and the eluate was combined into four fractions to obtain fractions 7-6-1 to 7-6-6 in order, and fraction 7-6-3 was loaded onto an Agilent C18 high performance liquid chromatography column for separation, where the mobile phase was a 55% aqueous methanol solution, the flow rate was 3mL / min, and the detector was a 210nm ultraviolet detector, and monomer compound 1 was obtained at a retention time of 59 minutes, and monomer compound 2 was obtained at a retention time of 62 minutes.

[0022] (3) Structure identification: Using deuterium-substituted dimethyl sulfoxide as the solvent, a Bruker AvanceII 500M nuclear magnetic resonance spectrometer is used to measure the nuclear magnetic resonance spectra of the separated compounds 1 and 2, and the molecular formulas are estimated using the mass spectra. A circular dichroism analyzer J-810-150S is used to measure the circular dichroism spectra of compounds 1 and 2, and DP4+ software is used to calculate the three-dimensional structures of compounds 1 and 2. The structure of the product is finally identified based on the nuclear magnetic resonance spectra, CD results and calculation results.

[0023] The spectral data of Compound 1 is as follows: 1 H-NMR (500 Hz, DMSO-d6) δ : 3.14 (1H, d, J = 13.5 Hz, H-1a), 4.17 (1H, d, J = 13.5 Hz, H-1b), 9.45 (1H, s, H-3OH), 6.63 (1H, d, J = 8.0 Hz, H-4), 7.00 (1H, t, J = 8.0 Hz, H-5), 6.72 (1H, d, J = 8.0 Hz, H-6), 6.56 (1H, d, J = 12.5 Hz, H-8), 6.01 (1H, d, J = 12.5Hz, H-9), 3.72 (1H, q, J = 6.0 Hz, H-11), 0.87 (3H, d, J = 6.0 Hz, H-12), 5.04 (1H, d, J = 12.5 Hz, H-1'a), 5.23 (1H, d, J = 12.5 Hz, H-1'b), 9.67 (1H, s, H-3'OH), 6.83 (1H, d, J = 8.0 Hz, H-4'), 7.05 (1H, t, J = 8.0 Hz, H-5'), 6.76 (1H, d, J = 8.0 Hz, H-6'), 4.04 (1H, d, J = 10.0Hz, H-8'), 4.54 (1H, d, J = 10.0 Hz, H-9'), 3.66 (1H, s, H-10'), 2.17 (3H, s, H-12'). 13C-NMR (125 Hz, DMSO-d6) δ : 59.5 (C-1), 126.8 (C-2), 153.3(C-3), 114.4 (C-4), 128.3 (C-5), 121.2 (C-6), 137.4 (C-7), 131.1 (C-8), 137.1 (C-9), 93.7 (C-10), 81.7 (C-11), 12.9 (C-12), 61.0 (C-1'), 122.8 (C-2'), 156.1 (C-3'), 115.3 (C-4'), 128.6 (C-5'), 123.3 (C-6'), 139.3 (C-7'), 59.8 (C-8'), 79.3 (C-9'), 79.7 (C-10'), 209.5 (C-11'), 28.0 (C-12').

[0024] The HMBC spectrum of compound 1 is shown below. [ka]

[0025] The NOESY spectrum of compound 1 is shown below. [ka]

[0026] The spectral data of compound 2 is as shown below. 1H-NMR (500 Hz, DMSO-d6) δ : 4.33 (1H, d, J = 13.5 Hz, H-1a), 5.11 (1H, d, J = 13.5 Hz, H-1b), 9.62 (1H, s, H-3OH), 6.83 (1H, d, J = 8.0 Hz, H-4), 7.16 (1H, t, J = 8.0Hz, H-5), 6.85 (1H, d, J = 8.0 Hz), 6.63 (1H, d, J = 12.5 Hz, H-8), 5.85 (1H, d, J = 12.5 Hz, H-9), 4.31 (1H, q, J = 6.5 Hz, H-11), 1.31 (3H, d, J = 6.5 Hz, H-12), 4.33 (1H, d, J = 13.5 Hz, H-1’a), 5.27 (1H, d, J = 13.5 Hz, H-1’b), 9.40 (1H, s, H-3’OH), 6.58 (1H, d, J = 7.8 Hz, H-4’), 6.53 (1H, t, J = 7.8 Hz, H-5’), 6.82 (1H, d, J = 7.8 Hz, H-6’), 3.84 (1H, d, J = 10.0 Hz, H-8’), 3.75 (1H, d, J = 10.0 Hz, H-9’), 4.01 (1H, s, H-10’), 2.14 (3H, s, H-12’)。 13 C-NMR (125 Hz, DMSO-d6) δ : 59.1 (C-1), 126.0 (C-2), 154.0 (C-3), 115.2 (C-4), 128.6 (C-5), 122.1 (C-6), 137.5 (C-7), 131.6 (C-8), 132.9 (C-9), 92.5 (C-10), 84.6 (C-11), 20.7 (C-12), 64.0 (C-1’), 126.4 (C-2’), 154.4 (C-3’), 113.8 (C-4’), 127.9 (C-5’), 119.8 (C-6’), 136.7 (C-7’), 52.5 (C-8’), 78.7 (C-9’), 91.5 (C-10’), 205.3 (C-11’), 27.7 (C-12’).

[0027] The HMBC spectrum of compound 2 is shown below. [ka]

[0028] The NOESY spectrum of compound 2 is shown below. [ka]

[0029] Example 2 Study on the anti-inflammatory activity of compound 1-2 prepared in Example 1 Culture of mouse RAW 264.7 macrophages: RAW 264.7 macrophages are inoculated into high-carbohydrate DMEM medium containing 10% fetal bovine serum (<0.5EU / mL), 1% penicillin and streptomycin, and cultured in a 37℃, 5% CO2 incubator. When cell coverage reaches approximately 90%, discard the supernatant and directly add 37℃ medium and spray it on the cells for subculture. Cells in the logarithmic growth phase are harvested and used for subsequent experiments.

[0030] Preparation of LPS-induced RAW 264.7 macrophage inflammation model: Logarithmic growth phase RAW 264.7 cells were taken at 1 × 10 per well. 4The cells were seeded into a 96-well cell culture plate, and after 24 hours for the cells to adhere, a normal control group, an LPS model group, a positive control group and a compound group were placed, with 6 wells for each group. For the normal control group and the LPS model group, firstly, culture the cells in serum-free DMEM medium; for the compound group, culture the cells in serum-free DMEM containing compound 1 or compound 2 at a final concentration of 40.00, 20.00, 10.00, 5μM, respectively; for the positive control group, culture the cells in serum-free DMEM containing L-NAME (nitric oxide synthase inhibitor) at a final concentration of 200μM; after culturing the cells for 4 hours as above, the normal control group continues to be cultured in serum-free DMEM, and the other groups are stimulated by adding LPS at a final concentration of 1μg / mL; after 24 hours, collect 50μL of medium per well, use nitric oxide screening kit to detect the secretion of NO, and add 10μL of MTT at a concentration of 5g / L to each well; continue culturing for 4 hours, discard the supernatant, add 150μL of DMSO to each well, shake for 10 minutes, and measure the absorbance of each well under 570nm.

[0031] The MTT results showed that the IC 50 is greater than 100 μM (IC 50 The results of the anti-inflammatory experiment are shown in FIG. 13. Compared with the model group, compound 1 and compound 2 inhibited the release of NO to different degrees depending on the concentration, among which, at a concentration of 5 μM, both showed better inhibitory activity than the positive control group. Therefore, it is obvious that compound 1 and compound 2 have good anti-inflammatory activity.

[0032] Finally, the following should be mentioned: the above embodiments are only for explaining the technical means of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the above embodiments, it is possible to modify the technical means described in the above embodiments, or to implement equivalent replacements for part or all of the technical features, and it is understood by those skilled in the art that such modifications and replacements do not depart from the essence of the corresponding technical means of the embodiments of the present invention.

[0033] [Note] [Appendix 1] A polyketide compound having the structure shown in the following formula, or a pharma- ceutically acceptable salt thereof. [ka]

[0034] [Appendix 2] The endophytic fungus of the genus Alternaria (Alternaria sp.) HJT-Y7 was deposited at the Center of Ordinary Microorganisms, China Committee for the Preservation and Management of Microbial Species, on May 6, 2022, with the deposit number CGMCC No. 40166 and the address of the depository institution at No. 3, Hospital No. 1, Beichen West Road, Chaoyang District, Beijing.

[0035] [Appendix 3] Step (1) of inoculating the Alternaria sp. HJT-Y7 described in Appendix 2 into a fungal No. 4 medium, culturing it with shaking, inoculating the resulting fermented liquid together with the mycelium into a rice solid medium, and allowing it to stand at 20 to 30°C for 10 to 40 days for fermentation to obtain a solid fermentation product; and (2) extracting the solid fermentation product obtained in step (1) with methanol, filtering the extract, loading the obtained extract onto a silica gel chromatography column, performing gradient elution using a mobile phase of chloroform / methanol in a volume ratio of 100:0 to 0:100, and obtaining fractions 1 to 16 in sequence based on the TLC results, loading fraction 7 onto a silica gel chromatography column, performing gradient elution using a mobile phase of petroleum ether / ethyl acetate in a volume ratio of 10:1 to 10:9, and obtaining fractions 7-1 to 7-10 in sequence based on the TLC results, loading fraction 7-6 onto a Sephadex LH-20 gel column, performing elution using a mobile phase of a dichloromethane / methanol mixture in a volume ratio of 1:1, and obtaining fractions 7-6-1 to 7-6-6 in sequence, loading fraction 7-6-3 onto an Agilent C18 high performance liquid chromatography column, performing elution using a mobile phase of 55% aqueous methanol, and obtaining compound 1 and compound 2.

[0036] [Appendix 4] The production method according to Appendix 3, wherein the shaking culture in step (1) is performed at 20 to 30° C. at 100 to 200 r / min.

[0037] [Appendix 5] The method for producing the solid rice medium in step (1) is obtained by preparing rice and pure water in a mass / volume ratio of 80:80 to 120 g / mL.

[0038] [Appendix 6] The production method described in Appendix 3, wherein the fungal No. 4 medium in step (1) is composed of 2% mannitol, 2% glucose, 0.5% yeast extract, 1% peptone, 0.05% KH2PO4, 0.03% MgSO4·7H2O, 0.1% corn steep liquor, and deionized water.

[0039] [Appendix 7] The production method described in Appendix 3, wherein in the gradient elution in step (2), the volume ratio of chloroform / methanol is 100:0, 100:1, 100:2, 100:3, 100:5, 100:10, or 0:100.

[0040] [Appendix 8] The method for producing according to Appendix 3, wherein in the gradient elution in step (2), the volume ratio of petroleum ether / ethyl acetate is 10:1, 10:3, 10:5, 10:6, 10:7, or 10:9.

[0041] [Appendix 9] A pharmaceutical composition comprising the polyketide compound described in Appendix 1 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.

[0042] [Appendix 10] Use of the polyketide compound or a pharma- ceutically acceptable salt thereof according to Appendix 1 or the pharmaceutical composition according to Appendix 9 for the manufacture of an anti-inflammatory drug.

Claims

1. A polyketide compound having the structure shown in the following formula, or a pharma- ceutically acceptable salt thereof. [Formula 1]

2. The endophytic fungus of the genus Alternaria (Alternaria sp.) HJT-Y7 was deposited at the Center of Ordinary Microorganisms of the China Committee for the Preservation and Management of Microorganisms on May 6, 2022, with the deposit number CGMCC No. 40166 and the address of the depository institution at No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing.

3. Step (1): inoculating the Alternaria sp. HJT-Y7 according to claim 2 into a fungal No. 4 medium, culturing it under shaking, inoculating the resulting fermented liquid together with the mycelium into a rice solid medium, and allowing it to stand at 20-30°C for 10-40 days for fermentation to obtain a solid fermentation product; The solid fermentation product obtained in step (1) is extracted with methanol and filtered; the obtained extract is loaded onto a silica gel chromatography column, and gradient elution is performed with a mobile phase of chloroform / methanol in a volume ratio of 100:0 to 0:100, and fractions 1 to 16 are obtained in sequence according to the TLC results; fraction 7 is loaded onto a silica gel chromatography column, and gradient elution is performed with a mobile phase of petroleum ether / ethyl acetate in a volume ratio of 10:1 to 10:9, and fractions 7-1 to 7-10 are obtained in sequence according to the TLC results; fraction 7-6 is loaded onto a Sephadex LH-20 gel column, and elution is performed with a mobile phase of a dichloromethane / methanol mixture in a volume ratio of 1:1, and fractions 7-6-1 to 7-6-6 are obtained in sequence; fraction 7-6-3 is purified by Agilent and (2) loading the mixture onto a C18 high performance liquid chromatography column and eluting the mixture with a 55% aqueous methanol solution as the mobile phase to obtain compound 1 and compound 2.

4. The method according to claim 3, wherein the shaking culture in step (1) is performed at 20 to 30° C. and at 100 to 200 r / min.

5. The method according to claim 3, wherein the rice solid medium in step (1) is prepared by preparing rice and pure water in a mass / volume ratio of 80:80 to 120 g / mL.

6. The fungal No. 4 medium in step (1) is composed of 2% mannitol, 2% glucose, 0.5% yeast extract, 1% peptone, 0.05% KH 2 P.O. 4 , 0.03% MgSO 4 ・7H 2 4. The method according to claim 3, wherein the composition is 0.05% corn steep liquor, 0.1% corn steep liquor, and deionized water.

7. 4. The method according to claim 3, wherein in the gradient elution in step (2), the volume ratio of chloroform to methanol is 100:0, 100:1, 100:2, 100:3, 100:5, 100:10, or 0:

100.

8. 4. The method of claim 3, wherein in the gradient elution in step (2), the volume ratio of petroleum ether / ethyl acetate is 10:1, 10:3, 10:5, 10:6, 10:7, or 10:

9.

9. A pharmaceutical composition comprising the polyketide compound of claim 1 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.

10. Use of the polyketide compound according to claim 1 or a pharma- ceutically acceptable salt thereof or the pharmaceutical composition according to claim 9 for the manufacture of an anti-inflammatory drug.

Citation Information

Patent Citations

  • Preparation method and application of polyketone compound with anti-novel coronavirus activity

    CN113248369A

  • Polyketone compound and preparation method thereof

    CN113277998A

  • Purine and imidazopyridine derivatives for immunosuppression

    JP2008534689A

  • Polyketide compounds having anti-inflammatory activity and methods for producing and using same

    JP2024542325A